B

Blueprint Medicines Corp
D

BPMC

91.790
USD
-4.69
(-4.86%)
مغلق
حجم التداول
33,241
الربح لكل سهم
-4
العائد الربحي
-
P/E
-44
حجم السوق
5,831,036,670
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ABBV
    ABBV
    -2.390
    (-1.36%)
    173.030 USD
    AMGN
    AMGN
    -7.11
    (-2.67%)
    258.81 USD
    BMY
    BMY
    -0.830
    (-1.44%)
    56.830 USD
    GILD
    GILD
    -2.130
    (-2.30%)
    90.630 USD
    GSK
    GSK
    -0.545
    (-1.59%)
    33.690 USD
    JNJ
    JNJ
    -1.660
    (-1.13%)
    144.730 USD
    LLY
    LLY
    -13.61
    (-1.75%)
    764.69 USD
    MRK
    MRK
    -1.770
    (-1.77%)
    98.300 USD
    PFE
    PFE
    -0.560
    (-2.12%)
    25.870 USD
    REGN
    REGN
    -25.38
    (-3.43%)
    714.50 USD
    VRTX
    VRTX
    -21.90
    (-4.67%)
    447.46 USD
    المزيد
الأخبار

العنوان: Blueprint Medicines Corp

القطاع: Healthcare
الصناعة: Biotechnology
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.